• Je něco špatně v tomto záznamu ?

Investigation of the efficacy and tolerability of Dr Michaels® (also branded as Eczitinex® and Itchinex Eczitinex®) topical products in the treatment of atopic dermatitis in children

K. França, J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, M. Tirant, P. Bayer, M. Coburn, P. Anderson, B. Donnelly, T. Kennedy, J. Gaibor, M. Arora, L. Clews, F. Novotny, MG. Roccia, GK. Maximov, T. Lotti,

. 2016 ; 30 (2 Suppl 3) : 55-63.

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001371

Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinex®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinex®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinex®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinex®) product family is a safe and effective treatment option for AD.

000      
00000naa a2200000 a 4500
001      
bmc19001371
003      
CZ-PrNML
005      
20190308125913.0
007      
ta
008      
190107s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)27498659
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a França, K $u Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.
245    10
$a Investigation of the efficacy and tolerability of Dr Michaels® (also branded as Eczitinex® and Itchinex Eczitinex®) topical products in the treatment of atopic dermatitis in children / $c K. França, J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, M. Tirant, P. Bayer, M. Coburn, P. Anderson, B. Donnelly, T. Kennedy, J. Gaibor, M. Arora, L. Clews, F. Novotny, MG. Roccia, GK. Maximov, T. Lotti,
520    9_
$a Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinex®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinex®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinex®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinex®) product family is a safe and effective treatment option for AD.
650    _2
$a aplikace kožní $7 D000279
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a atopická dermatitida $x farmakoterapie $x terapie $7 D003876
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a masti $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D009824
650    12
$a fytoterapie $x škodlivé účinky $7 D008517
650    _2
$a kůže $x účinky léků $7 D012867
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hercogová, J $u 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Fioranelli, M $u Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
700    1_
$a Gianfaldoni, S $u Dermatological Department University of Pisa, Pisa, Italy.
700    1_
$a Chokoeva, A A $u Onkoderma - Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 7 Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria.
700    1_
$a Tchernev, G $u Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
700    1_
$a Wollina, U $u Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
700    1_
$a Tirant, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Bayer, P $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Coburn, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Anderson, P $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Donnelly, B $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Kennedy, T $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Gaibor, J $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Arora, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Clews, L $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Novotny, F $u PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic.
700    1_
$a Roccia, M G $u University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
700    1_
$a Maximov, G K $u Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria.
700    1_
$a Lotti, T $u Chair of Dermatology, University of Rome G. Marconi Rome, Italy.
773    0_
$w MED00008336 $t Journal of biological regulators and homeostatic agents $x 0393-974X $g Roč. 30, č. 2 Suppl 3 (2016), s. 55-63
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27498659 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190308130229 $b ABA008
999    __
$a ok $b bmc $g 1364068 $s 1039494
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 30 $c 2 Suppl 3 $d 55-63 $i 0393-974X $m Journal of Biological Regulators & Homeostatic Agents $n J Biol Regul Homeost Agents $x MED00008336
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace